Navigation Links
Covance to Present at UBS Global Life Sciences Conference
Date:9/18/2009

PRINCETON, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the UBS Global Life Sciences Conference on Monday, September 21, 2009 at 10:00 a.m. (ET). Investors may access a live webcast of the presentation at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward
2. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
3. Covance to Present at the Drug Information Associations 45th Annual Meeting
4. Covance Elects John McCartney to Companys Board of Directors
5. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
6. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
7. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
8. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
9. Covance Purchases Equity Stake in Caprion Proteomics
10. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
11. Covance Decides to Pursue Its Original Preclinical Strategy in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... with State Biotech Leaders to Develop Blueprint ... Development while Boosting Rhode Island,s Growing Biotech ... R.I., Dec. 14 Several of ... medicine and biotechnology gathered today at Brown ... importance of medical innovation in Rhode Island ...
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/14/2009)... completed the delivery of Brookfield Engineering’s Powder Flow Tester – ... with a smaller footprint and more compact design. , ... ... -- ThermoFab, a US-based thermoforming company, has completed the delivery ... from sheet metal to a plastic enclosure with a smaller ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
... Maxygen, Inc.,(Nasdaq: MAXY ), a biotechnology company ... that it will present at two,upcoming investor conferences. Russell ... Rodman and Renshaw 9th Annual Healthcare Conference Monday, ... 18th Annual Healthcare Conference Tuesday, November 6, 8:00 ...
... CAMBRIDGE, Mass., Oct. 25 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... of a,conference call at 8:00 a.m. ET on ... Company,s third-quarter 2007 financial and,operational results and upcoming ... be available on the webcast. Prior to the,conference ...
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
Other Biology Technology:Millennium to Webcast Third-Quarter 2007 Financial and Operational Results 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5
(Date:12/16/2009)... of Maryland School of Medicine researcher will lead the ... prominent scientists in the field of stem cell research. ... Medicine, was chosen by the National Heart, Lung and ... consortium of national experts, which will be called the ... be funded by a $30 million grant over seven ...
(Date:12/16/2009)... Dec. 2 DigitalPersona, Inc., a ... today announced an agreement with IBM to ... biometric fingerprint technology on IBM SurePOS 500 ... allows point-of-sale applications to more easily and ... can be linked to the individuals who ...
(Date:12/16/2009)... -- IgeaCare Solutions Inc. is pleased to announce ... communications company previously operating as IgeaCare Systems Inc. ... forward under new leadership and funding. ,, IgeaCare ... the position of Chief Executive Officer. Under his ... a superior servicing and support model; fast and ...
Breaking Biology News(10 mins):University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Food Security to be the Top Issue for EUs Science Chief 62345 1Food Security to be the Top Issue for EUs Science Chief 62345 2Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 1Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 2Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint 28R 29 15018 1Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint 28R 29 15018 2
... drug warfarin to prevent harmful clotting after a heart attack, ... can vary greatly and can be hard to predict. Some ... gene involved in blood clotting, according to a new study ... Journal of Medicine. , By looking at the genetic makeup ...
... function of the microRNA mir1, Drs. Nicholas Sokol ... the expression profile, transcriptional regulation and loss-of-function phenotype ... conserved miRNA, whose expression in mouse and humans ... Strikingly, their study shows that, in Drosophila embryos, ...
... at the University of North Carolina Hospitals arrived in ... glowing track record in helping to repair heart valves, ... gastric bypass operations for morbid obesity. , The new ... System, manufactured by Intuitive Surgical. UNC currently is the ...
Other Biology News:Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3